Anti-sulfatide IgM antibodies in peripheral neuropathy: To test or not to test?

C. Giannotta, D. Di Pietro, F. Gallia, E. Nobile-Orazio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and purpose: Anti-sulfatide immunoglobulin M (IgM) antibodies have been associated with different forms of neuropathies but their diagnostic role in neuropathy remains unclear. Methods: The clinical association of increased titers of anti-sulfatide IgM antibodies in 570 patients with neuropathy and related disorders examined in our laboratory since 2004 was reviewed. Sera were tested by enzyme-linked immunosorbent assay at the initial serum dilution of 1:32 000 and titrated by serial two-fold dilution. In all positive patients IgM antibodies to myelin-associated glycoprotein (MAG) were also measured by western blot. Results: High titers of anti-sulfatide antibodies were found in 39 patients including 33 (85%) who also had anti-MAG IgM. Six patients did not have anti-MAG IgM including five in whom moderately increased anti-sulfatide titers were associated with different forms of neuropathy. One patient with a demyelinating neuropathy and IgM monoclonal gammopathy had markedly increased anti-sulfatide titers (1:256 000). Conclusions: Increased titers of anti-sulfatide IgM antibodies are not infrequent in patients with neuropathy where they are often associated with a concomitant reactivity to MAG. A selective reactivity to sulfatide, however, is rarely found and is associated with different forms of neuropathy limiting its usefulness in the diagnosis of neuropathy.

Original languageEnglish
Pages (from-to)879-882
Number of pages4
JournalEuropean Journal of Neurology
Volume22
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Sulfoglycosphingolipids
Peripheral Nervous System Diseases
Immunoglobulin M
Myelin-Associated Glycoprotein
Antibodies
Paraproteinemias
Serum
Anti-Idiotypic Antibodies
Western Blotting
Enzyme-Linked Immunosorbent Assay

Keywords

  • Antibodies
  • Autoimmunity
  • IgM
  • Neuropathy
  • Sulfatide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Anti-sulfatide IgM antibodies in peripheral neuropathy : To test or not to test? / Giannotta, C.; Di Pietro, D.; Gallia, F.; Nobile-Orazio, E.

In: European Journal of Neurology, Vol. 22, No. 5, 01.05.2015, p. 879-882.

Research output: Contribution to journalArticle

@article{9697792cd31e4650815133dc5146daf7,
title = "Anti-sulfatide IgM antibodies in peripheral neuropathy: To test or not to test?",
abstract = "Background and purpose: Anti-sulfatide immunoglobulin M (IgM) antibodies have been associated with different forms of neuropathies but their diagnostic role in neuropathy remains unclear. Methods: The clinical association of increased titers of anti-sulfatide IgM antibodies in 570 patients with neuropathy and related disorders examined in our laboratory since 2004 was reviewed. Sera were tested by enzyme-linked immunosorbent assay at the initial serum dilution of 1:32 000 and titrated by serial two-fold dilution. In all positive patients IgM antibodies to myelin-associated glycoprotein (MAG) were also measured by western blot. Results: High titers of anti-sulfatide antibodies were found in 39 patients including 33 (85{\%}) who also had anti-MAG IgM. Six patients did not have anti-MAG IgM including five in whom moderately increased anti-sulfatide titers were associated with different forms of neuropathy. One patient with a demyelinating neuropathy and IgM monoclonal gammopathy had markedly increased anti-sulfatide titers (1:256 000). Conclusions: Increased titers of anti-sulfatide IgM antibodies are not infrequent in patients with neuropathy where they are often associated with a concomitant reactivity to MAG. A selective reactivity to sulfatide, however, is rarely found and is associated with different forms of neuropathy limiting its usefulness in the diagnosis of neuropathy.",
keywords = "Antibodies, Autoimmunity, IgM, Neuropathy, Sulfatide",
author = "C. Giannotta and {Di Pietro}, D. and F. Gallia and E. Nobile-Orazio",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/ene.12658",
language = "English",
volume = "22",
pages = "879--882",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Anti-sulfatide IgM antibodies in peripheral neuropathy

T2 - To test or not to test?

AU - Giannotta, C.

AU - Di Pietro, D.

AU - Gallia, F.

AU - Nobile-Orazio, E.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background and purpose: Anti-sulfatide immunoglobulin M (IgM) antibodies have been associated with different forms of neuropathies but their diagnostic role in neuropathy remains unclear. Methods: The clinical association of increased titers of anti-sulfatide IgM antibodies in 570 patients with neuropathy and related disorders examined in our laboratory since 2004 was reviewed. Sera were tested by enzyme-linked immunosorbent assay at the initial serum dilution of 1:32 000 and titrated by serial two-fold dilution. In all positive patients IgM antibodies to myelin-associated glycoprotein (MAG) were also measured by western blot. Results: High titers of anti-sulfatide antibodies were found in 39 patients including 33 (85%) who also had anti-MAG IgM. Six patients did not have anti-MAG IgM including five in whom moderately increased anti-sulfatide titers were associated with different forms of neuropathy. One patient with a demyelinating neuropathy and IgM monoclonal gammopathy had markedly increased anti-sulfatide titers (1:256 000). Conclusions: Increased titers of anti-sulfatide IgM antibodies are not infrequent in patients with neuropathy where they are often associated with a concomitant reactivity to MAG. A selective reactivity to sulfatide, however, is rarely found and is associated with different forms of neuropathy limiting its usefulness in the diagnosis of neuropathy.

AB - Background and purpose: Anti-sulfatide immunoglobulin M (IgM) antibodies have been associated with different forms of neuropathies but their diagnostic role in neuropathy remains unclear. Methods: The clinical association of increased titers of anti-sulfatide IgM antibodies in 570 patients with neuropathy and related disorders examined in our laboratory since 2004 was reviewed. Sera were tested by enzyme-linked immunosorbent assay at the initial serum dilution of 1:32 000 and titrated by serial two-fold dilution. In all positive patients IgM antibodies to myelin-associated glycoprotein (MAG) were also measured by western blot. Results: High titers of anti-sulfatide antibodies were found in 39 patients including 33 (85%) who also had anti-MAG IgM. Six patients did not have anti-MAG IgM including five in whom moderately increased anti-sulfatide titers were associated with different forms of neuropathy. One patient with a demyelinating neuropathy and IgM monoclonal gammopathy had markedly increased anti-sulfatide titers (1:256 000). Conclusions: Increased titers of anti-sulfatide IgM antibodies are not infrequent in patients with neuropathy where they are often associated with a concomitant reactivity to MAG. A selective reactivity to sulfatide, however, is rarely found and is associated with different forms of neuropathy limiting its usefulness in the diagnosis of neuropathy.

KW - Antibodies

KW - Autoimmunity

KW - IgM

KW - Neuropathy

KW - Sulfatide

UR - http://www.scopus.com/inward/record.url?scp=84926416502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926416502&partnerID=8YFLogxK

U2 - 10.1111/ene.12658

DO - 10.1111/ene.12658

M3 - Article

C2 - 25597226

AN - SCOPUS:84926416502

VL - 22

SP - 879

EP - 882

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 5

ER -